Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
Ipsen announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s…
Read More...
Read More...